Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Fineline Cube May 26, 2026
Company Deals

Insilico Medicine and Eterna Therapeutics Expand AI-Driven Partnership into Skin Anti-Aging and Scientific Skincare

Fineline Cube May 26, 2026
Company Deals

ZBD Pharmaceutical Secures Marketing Rights for Teruisi’s CD20-Targeted ADC TRS005 in Relapsed/Refractory Non-Hodgkin Lymphoma

Fineline Cube May 26, 2026
Company Deals

Sinocelltech Files for Hong Kong Secondary Listing to Expand Global Capital Access and Therapeutic Portfolio

Fineline Cube May 25, 2026
Company Deals Medical Device

Lifetech Scientific to Acquire Starway Medical Technology in $276 Million Deal to Expand Structural Heart Portfolio

Fineline Cube May 25, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease

Fineline Cube May 26, 2026
Company Drug

China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn’s Disease

Fineline Cube May 26, 2026
Company Medical Device

NMPA Approves Synaptic Medical’s Cryoablation Device and Gene Methylation Detection Kit

Fineline Cube Jan 21, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval for two new medical devices:...

Company Drug

Huadong Medicine’s MediBeacon TGFR System Receives FDA Marketing Clearance

Fineline Cube Jan 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing clearance from the US...

Company Drug

MediLink’s YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced receiving another breakthrough therapy designation (BTD)...

Company Drug

Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes

Fineline Cube Jan 21, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment...

Company Drug

Arrowhead’s Plozasiran Accepted for FDA Review in Familial Chylomicronemia Syndrome

Fineline Cube Jan 21, 2025

US-based Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that the New Drug Application (NDA) for...

Company Deals

Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium

Fineline Cube Jan 21, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly...

Company Drug

GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU

Fineline Cube Jan 21, 2025

UK-based GSK plc (NYSE: GSK, LON: GSK) has announced receiving approval from the European Commission...

Company Drug

Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving another clearance from the...

Company Deals

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets

Fineline Cube Jan 21, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...

Company Drug

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2320 in AML

Fineline Cube Jan 21, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the first subject dosing in an...

Company Deals

Danaher Partners with Huashan Hospital to Develop Alzheimer’s Diagnostic Solutions

Fineline Cube Jan 21, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced a partnership between...

Company Drug

Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA

Fineline Cube Jan 21, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...

Company Deals

Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health

Fineline Cube Jan 21, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation...

Policy / Regulatory

NHSA Outlines 2025 Work Plan and 2024 Medical Insurance Status

Fineline Cube Jan 20, 2025

The National Healthcare Security Administration (NHSA) last week held a press conference, addressing questions regarding...

Company Drug

FDA Approves AstraZeneca’s Calquence for Mantle Cell Lymphoma

Fineline Cube Jan 20, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) last week revealed that the US Food and...

Company Deals Medical Device

NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business

Fineline Cube Jan 20, 2025

US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device...

Company Drug

MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis

Fineline Cube Jan 20, 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...

Policy / Regulatory

Tianjin Healthcare Official Gao Xue Under Investigation

Fineline Cube Jan 20, 2025

Gao Xue, director of the National High-value Medical Consumables Joint Procurement Office, member of the...

Medical Device Policy / Regulatory

US BIS Imposes Export Controls on Biotech Lab Instruments

Fineline Cube Jan 20, 2025

The Department of Commerce’s Bureau of Industry and Security (BIS) of the United States last...

Company

Junshi Biosciences Forecasts 29.71% Revenue Growth for 2024

Fineline Cube Jan 20, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has released its 2024 annual...

Posts pagination

1 … 229 230 231 … 672

Recent updates

  • Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China
  • Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis
  • NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking
  • Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease
  • CanSino Biologics Initiates Phase I/II Trial for PCV24 Pneumococcal Conjugate Vaccine with Enhanced Serotype Coverage
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Others

Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis

Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Company Drug

Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.